Company Filing History:
4 out of 637 
2 out of 12 
1 out of 81 Years Active: 2005-2016
Title: Mireille Sebbag: Pioneering Innovations in Rheumatoid Arthritis Treatment
Introduction
Mireille Sebbag is an esteemed inventor based in Toulouse, France, who has made significant contributions to the field of medical innovation. With a total of seven patents to her name, she stands out for her work on peptides that modulate the activity of macrophages, particularly in the treatment of rheumatoid arthritis.
Latest Patents
Sebbag's latest innovations include groundbreaking peptides with anti-inflammatory properties. One notable invention involves citrulline peptides that can activate macrophages induced by immune complexes associated with rheumatoid arthritis. These peptides promise to change the landscape of treatment for individuals suffering from this debilitating condition. Another remarkable patent pertains to novel citrulline peptides derived from fibrin. These peptides are recognizable by specific citrulline antiprotein autoantibodies related to rheumatoid arthritis, providing a new method for detecting these autoantibodies in biological samples.
Career Highlights
Throughout her career, Mireille has worked with prominent organizations that have helped shape her research. Notably, she has been associated with Biomerieux, Inc. and the Université Paul Sabatier, where her innovative ideas have flourished.
Collaborations
Throughout her journey, Mireille has collaborated with esteemed colleagues in the industry. Notable coworkers include Guy Serre and Christian Vincent, whose partnerships have likely enriched her work and expanded the impact of her inventions.
Conclusion
Mireille Sebbag is a trailblazer in the field of biomedical innovation, with patents that hold the potential to transform the treatment of rheumatoid arthritis. Her remarkable contributions, collaborations, and dedication to research underscore her role as a significant figure in the advancement of medical technology. The innovations stemming from her work are expected to make a lasting impact on patient care and treatment approaches in the years to come.